Zimmer Biomet Holdings, Inc.
NYSE:ZBHMedical - Devices
+$0.87 today
- Market cap
- $19.55B
- Beta
- 0.47
- P/E (TTM)
- 22.5
- EPS (TTM)
- $3.90
- Dividend yield
- 1.09%
Volume 2.34M
Average 2.28M
ZBH Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Zimmer Biomet Holdings, Inc.NYSE: ZBH
Research & Development · Q2 FY2026 · quarter ended Jun 2026
Research & development declines year over year
Q2 FY2026 research & development of $104.8M fell 7.5% year over year, behind the -0.2% change in trailing-twelve-month research & development. Sequentially, it rose 1.4% from the prior quarter. Over 3 fiscal years it compounded at +4.1% a year.
Context
- Research & development amounted to 5.6% of revenue in FY2025, down 0.1 pp from a year earlier.
- Research & development increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -7.5% toward the trailing-twelve-month pace of -0.2%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 458.5M USD
- Year-over-year change
- +4.8%
- 4-year CAGR
- +1.3%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 458.5M | +4.8% |
| FY2024 | 2024-12-31 | 437.4M | -4.6% |
| FY2023 | 2023-12-31 | 458.7M | +13.0% |
| FY2022 | 2022-12-31 | 406M | -6.8% |
| FY2021 | 2021-12-31 | 435.8M | — |
Research & Development vs competitors
How ZBH compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -0.2% is the 8th highest of 10, against a peer median of +1.2%.
- Research & development amounts to 5.2% of revenue for ZBH, versus a peer median of 7.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jul 2026 | $2.92B USD | +4.9% | +2.1% | 7.8% | |
| LTM Jun 2026 | $2.15B USD | +17.3% | +15.8% | 10.3% | |
| LTM Jun 2026 | €1.72B EUR | -2.6% | -6.7% | 9.7% | |
| LTM Jun 2026 | $1.66B USD | +10.1% | +8.8% | 6.4% | |
| LTM Jun 2026 | $1.32B USD | +1.2% | +7.1% | 6.5% | |
| LTM Jun 2026 | $1.09B USD | +3.3% | +4.5% | 16.7% | |
| LTM Jun 2026 | $442.9M USD | -0.2% | +4.1% | 5.2% | |
| LTM Jun 2026 | $377M USD | +0.9% | +6.6% | 9.1% | |
| FY2025 | $346M USD | +0.9% | +0.1% | 5.6% | |
| LTM Mar 2026 | $61.4M USD | -16.9% | +5.2% | 7.4% | |
| Peer median (excluding ZBH) | — | +1.2% | +5.2% | 7.8% | |
Competitors are the stored peer set for ZBH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 6.83B | 6.94B | 7.39B | 7.68B | 8.23B |
| Cost of Revenue | 1.96B | 2.02B | 2.08B | 2.19B | 3.16B |
| Gross Profit | 4.87B | 4.92B | 5.31B | 5.49B | 5.07B |
| Gross Margin | 71.3% | 70.9% | 71.8% | 71.5% | 61.6% |
| Research & Development | 435.8M | 406M | 458.7M | 437.4M | 458.5M |
| Selling, General & Admin | 2.84B | 2.76B | 2.84B | 2.93B | 3.25B |
| Operating Expenses | 4.01B | 4.22B | 4.03B | 4.2B | 3.71B |
| Depreciation & Amortization | 937.7M | 926.4M | 951.7M | 996.3M | 1.09B |
| EBITDA | 1.65B | 1.49B | 2.22B | 2.25B | 2.22B |
| EBITDA Margin | 24.1% | 21.5% | 30.0% | 29.3% | 26.9% |
| Operating Income | 860.3M | 696.3M | 1.28B | 1.29B | 1.36B |
| Operating Margin | 12.6% | 10.0% | 17.3% | 16.7% | 16.5% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 208.4M | 164.8M | 201.2M | 218M | 292.8M |
| Other Income / Expenses | (361.3M) | (292.8M) | (210.4M) | (249.1M) | (531.4M) |
| Income Before Tax | 499M | 403.5M | 1.07B | 1.04B | 830.8M |
| Pre-Tax Margin | 7.3% | 5.8% | 14.4% | 13.5% | 10.1% |
| Income Tax Expense | 53.5M | 112.3M | 42.2M | 131.4M | 125.7M |
| Net Income | 401.6M | 231.4M | 1.02B | 903.8M | 705.2M |
| Net Margin | 5.9% | 3.3% | 13.8% | 11.8% | 8.6% |
| EPS (Basic) | 1.87 | 1.10 | 4.91 | 4.45 | 3.56 |
| EPS (Diluted) | 1.85 | 1.10 | 4.88 | 4.43 | 3.55 |
| Weighted Avg Shares | 214.86M | 209.6M | 208.7M | 203.1M | 198M |
| Weighted Avg Shares (Diluted) | 216.71M | 210.3M | 209.7M | 203.9M | 198.7M |
Zimmer Biomet Holdings, Inc.
NYSE:ZBH
Intrinsic Alpha fair value
Locked
Current Price
$103.32
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.